IRHOM2, although not an absolutely perfect hallmark for NASH pathogenesis, predisposes to hepatosteatosis, early liver fibrosis, and even hepatocellular carcinoma (HCC), and was previously treated as an important influencing factor that served as an inflammatory promoter in the long‐term mortality of patients with NASH. The gene discussed is RHBDF2; the disease is metabolic dysfunction-associated steatohepatitis.